📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
24 announcements match the current filters (relevance ≥ 5).
Hester Biosciences Q3 FY26: PAT Surges 140% YoY; H9N2 Vaccine License Received
Hester Biosciences reported a strong 140% YoY increase in standalone PAT for Q3 FY26, driven by a favorable product mix and cost discipline. While the Poultry Healthcare division grew by 32% in Q3, the Animal Healthcare division saw a 38% decline due to timing delays in government-led immunization programs. The company achieved a major regulatory milestone by receiving manufacturing licenses for the H9N2 Avian Influenza vaccine and successfully capitalized its fill/finish facility, doubling its drug product capacity.
Key Highlights
Standalone PAT increased by 140% YoY in Q3 FY26, supported by improved operational discipline.
Poultry Healthcare division revenue grew 32% in Q3 and 17% over the 9-month period.
Received marketing and manufacturing licenses for the H9N2 Avian Influenza vaccine post-quarter end.
Capitalized a new fill/finish facility from the INR 182 crore CWIP, doubling drug product capacity.
Animal Healthcare revenue declined 38% in Q3 due to tender delays, with recovery expected in Q4 FY26.
👀 What to Watch
Investors should focus on the upcoming launch of the H9N2 vaccine and the resumption of government immunization tenders in Q4. The doubling of manufacturing capacity positions the company for significant scale-up in both domestic and export markets.
Hester Biosciences Q3 Standalone PAT Jumps 140% to ₹106.7M; Poultry Division Grows 32%
Hester Biosciences reported a robust standalone performance for Q3 FY26, with PAT surging 140% YoY to ₹106.69 million on a 12% revenue increase. The growth was primarily driven by the Poultry Healthcare division, which grew 32%, while the Animal Healthcare division faced a 38% decline due to delayed government tenders. Consolidated PAT for the quarter fell 18% to ₹93.10 million, largely due to losses in the African subsidiary. However, the company has doubled its drug product capacity and expects a strong Q4 as national immunization programs resume.
Key Highlights
Standalone Q3 PAT rose 140% to ₹106.69 million, while standalone revenue grew 12% to ₹703.54 million.
Poultry Healthcare division delivered 32% growth in Q3, supported by a new H9N2 Avian Influenza vaccine license.
Animal Healthcare revenue declined 38% due to deferred government orders, which are scheduled to commence in February 2026.
Consolidated 9M FY26 PAT stands at ₹409.37 million, representing a 50% growth over the previous year.
Capitalized a new fill-finish facility during the quarter, effectively doubling the company's drug product capacity.
👀 What to Watch
Investors should view the standalone margin expansion and poultry segment growth as positive indicators of operational efficiency. The temporary dip in animal healthcare revenue is expected to reverse in Q4, making the current performance a strong base for year-end results.
Hester Biosciences Q3 Standalone PAT Surges 140% YoY to ₹106.7 Mn; CEO Re-appointed
Hester Biosciences delivered a robust standalone performance for Q3 FY26, with Net Profit jumping 140% YoY to ₹106.69 million. Standalone revenue grew by 12% YoY, driven primarily by a 32% growth in the Poultry Healthcare segment. However, consolidated PAT declined by 18% YoY to ₹93.10 million, largely due to a sharp reduction in 'Other Income' compared to the previous year. The board also confirmed the re-appointment of founder Rajiv Gandhi as CEO and Managing Director for a three-year term starting April 2026.
Key Highlights
Standalone Revenue from Operations increased 12% YoY to ₹703.54 million in Q3 FY26.
Standalone Net Profit (PAT) rose 140% YoY to ₹106.69 million from ₹44.39 million.
Poultry Healthcare segment revenue grew 32% YoY to ₹513.02 million.
Consolidated PAT fell 18% YoY to ₹93.10 million, impacted by lower other income of ₹6.69 million vs ₹78.09 million YoY.
Mr. Rajiv Gandhi re-appointed as CEO & Managing Director for 3 years effective April 1, 2026.
👀 What to Watch
Investors should take note of the strong operational recovery in the standalone business and the significant growth in the poultry segment. The re-appointment of the founder-CEO ensures leadership continuity, making the stock a 'Watch' for sustained margin improvement.
Hester Biosciences Receives Manufacturing License for H9N2 Avian Influenza Vaccine
Hester Biosciences has received a manufacturing license from the Food & Drugs Control Administration for its Low Pathogenic Avian Influenza (H9N2) vaccine for poultry. The H9N2 strain is a persistent challenge in the poultry industry, causing significant economic losses through reduced egg production and broiler performance. This vaccine was developed using technology acquired from ICAR-NIHSAD via Agrinnovate India. This regulatory milestone strengthens Hester's poultry healthcare portfolio and addresses a year-round comorbidity issue in the sector.
Key Highlights
Received manufacturing and marketing license from FDCA for Inactivated Avian Influenza H9N2 vaccine.
Technology for the vaccine was acquired from ICAR-NIHSAD through Agrinnovate India.
Targets the H9N2 strain which causes significant economic losses in both layer and broiler poultry segments.
The vaccine aims to prevent irreversible drops in egg production and high mortality rates associated with the virus.
Strengthens the company's prevention-led poultry healthcare product pipeline.
👀 What to Watch
Investors should view this as a positive development that expands Hester's product offerings in the animal healthcare market. Monitor the commercial launch timeline and the subsequent impact on the poultry segment's revenue growth.
